Retension Pharmaceuticals Inc. RTSN · SEC Filings

website

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ...

Price12.39

Market Cap103.23 M

Float2.89 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer

Oct 22, 2026

8-K

Retension Pharmaceuticals Announces Amendments to Certificate of Incorporation and Bylaws in Connection with IPO

Oct 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Oct 9, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 14, 2026

S-1MEF

Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]

Oct 8, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Oct 8, 2026

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Oct 7, 2026

S-1/A

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Oct 5, 2026

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

Sep 18, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Wong Robert (Reporting)

Nov 4, 2026

Wong Robert (Reporting)

Nov 4, 2026

Keller Eric L. (Reporting)

Oct 22, 2026

B Group, Inc. (Reporting)

Oct 16, 2026

SCHEDULE 13G

B Group, Inc. (Filed by)

Oct 16, 2026

SCHEDULE 13G

PVG ASSET MANAGEMENT CORP (Filed by)

Oct 16, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 9, 2026